SBI Securities Co. Ltd. Purchases 10,548 Shares of Novo Nordisk A/S $NVO

SBI Securities Co. Ltd. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 73.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,884 shares of the company’s stock after purchasing an additional 10,548 shares during the period. SBI Securities Co. Ltd.’s holdings in Novo Nordisk A/S were worth $1,381,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. True Wealth Design LLC raised its position in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $25,000. Strengthening Families & Communities LLC acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at $30,000. NewSquare Capital LLC grew its position in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the period. Finally, Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter valued at $37,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO opened at $47.71 on Friday. The company has a fifty day moving average price of $53.61 and a two-hundred day moving average price of $53.94. The firm has a market capitalization of $213.03 billion, a PE ratio of 13.75 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Wall Street Analyst Weigh In

NVO has been the topic of several research analyst reports. Morgan Stanley reaffirmed an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, Jefferies Financial Group started coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating on the stock. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $56.07.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA says it will target mass-marketed, unapproved compounded drug copies, which reduces the competitive threat from low-cost copycats and helped lift sentiment. Novo Nordisk shares rebound as FDA targets illegal drug copies – Reuters
• Positive Sentiment: Some analysts view the recent selloff as overdone and argue NVO’s strong cash flow, first-mover Wegovy advantages and promising pipeline (CagriSema) make the pullback a buying opportunity for long-term holders. Novo Nordisk: The Selloff Is A Blessing In Disguise – Seeking Alpha
• Positive Sentiment: Novo has announced it will pursue legal action against Hims & Hers over compounded Wegovy copies — a defensive step that could limit spread of low-cost alternatives if successful. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding – Reuters
• Neutral Sentiment: Company disclosure shows trading by board members and executives — useful for monitoring insider behavior but not immediately directional. Trading in Novo Nordisk shares by board members, executives – GlobeNewswire
• Neutral Sentiment: Company declared a dividend (record/ex-dividend dates published) — supportive for income investors but not a cure for near-term volume/price headwinds.
• Negative Sentiment: Hims & Hers launched a $49–$99 compounded oral semaglutide offering, sharply undercutting Wegovy’s price and triggering market panic about pricing erosion and access to cheap compounding alternatives. Hims and Hers Health launches copy of Wegovy pill at $49 – Reuters
• Negative Sentiment: Citi warns that inability to curb compounded semaglutide use is a lingering risk to Novo’s pricing power and investor sentiment. Citi flags lingering risks to Novo despite strong weight-loss portfolio – Proactive Investors
• Negative Sentiment: Competitive dynamics: Eli Lilly’s strong guidance and manufacturing scale are shifting market share and investor preference toward Lilly, increasing near-term pressure on Novo’s revenue outlook. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles – MarketBeat
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell for the first time, highlighting geographic and competitive pressures. Novo reports first Ozempic sales drop in greater China region – Reuters

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.